ライフサイエンスコーパス: DDS

1 DDS (0-39 pts.), ECD status (+ or -), and preservation t

2 DDS and ECD are determined by a calculation of risk from

3 DDS identified a subgroup of ECD- kidneys, those with DD

4 DDS is inherited in an autosomal dominant fashion, imply

5 DDS mutations cluster predominantly in zinc fingers (ZF)

6 DDS was superior to ECD status and RI in its correlation

7 DDS was the best predictor of outcome after deceased don

8 ) was calculated from home foods only, and a DDS >/=4 constituted minimum dietary diversity (MDD).

9 of recent advances in mechanically activated DDS.

10 equacy were mostly obtained when both SR and DDS were maximal.

11 Overall, light-activated nanomedicines and DDSs are expected to provide more effective therapies ag

12 tide as a targeting moiety in the anticancer DDS substantially enhanced the efficacy of chemotherapy,

13 ice and wild-type mice after 12 weeks of AOM/DDS exposure.

14 This liquid metal-based DDS with fusible and degradable behaviour under physiolo

15 an distribution of a gold nanoparticle-based DDS containing both a passive and active targeting moiet

16 This study was designed to compare DDS, ECD status, and RI as predictors of outcome after d

17 of drug-resistant strains; however, dapsone (DDS) resistance continues to be reported.

18 tion method based on dichlorodimethylsilane (DDS)-Tween-20 for in vitro single-molecule studies, whic

19 e associated with Wilms' tumor, Denys Drash (DDS), and Frasier syndromes.

20 DDS.DWI may be a useful diagnostic tool for DDS in patients with end-stage renal disease.

21 mutations, a heteroduplex DDS M. leprae (HD-DDS-ML) assay was developed for the simultaneous detecti

22 The HD-DDS-ML assay detected as few as 100 M. leprae organisms

23 The HD-DDS-ML assay provides a new tool for the simultaneous de

24 fected with 14 separate strains using the HD-DDS-ML assay.

25 Based on these mutations, a heteroduplex DDS M. leprae (HD-DDS-ML) assay was developed for the si

26 zed to receive either a GA (control) or a HF-DDS graft (test).

27 this investigation, the tissue engineered HF-DDS graft was safe and capable of generating keratinized

28 man fibroblast-derived dermal substitute (HF-DDS), compared to a gingival autograft (GA) consisting o

29 ratinized tissue and shrank less than the HF-DDS graft, but the test graft generated tissue that appe

30 was born in Toronto, Canada and received his DDS degree from the University of Toronto in 1957.

31 f HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and l

32 We were also interested to see if DDS or ECD could identify kidneys most likely to benefit

33 ffect" in the pathogenesis of brain edema in DDS.DWI may be a useful diagnostic tool for DDS in patie

34 bsolute increase and the rate of increase in DDS clients aged 3 to 5 years with autism were higher th

35 years with autism were higher than those in DDS clients of the same ages with any eligible condition

36 ozygosity for the Wt1tmT396 mutation induces DDS in heterozygous and chimeric (Wt1tmT396/+<-->+/+) mi

37 ere are three key features of this nanoscale DDS: (a) use of functionalized SWNTs as a biocompatible

38 n individuals in prey aggregations (negative DDS, the preferential selection by predators of spatiall

39 Both positive and negative DDS on prey groups have been documented in nature but th

40 artificial prey (positive, negative, and non-DDS) are displayed through different combinations of the

41 ria and glomerulosclerosis characteristic of DDS patients.

42 Numerous forms of DDS on artificial prey (positive, negative, and non-DDS)

43 The estimated prevalence of DDS clients aged 3 to 5 years with autism increased for

44 In vitro study reveals that our DDS exhibit excellent properties like biocompatibility,

45 The proposed DDS minimizes the uptake of the drug by normal cells and

46 The relevant DDS can be activated to promote drug release by differen

47 n employed in the design of light-responsive DDSs.

48 A 7-food group dietary diversity score (DDS) was calculated from home foods only, and a DDS >/=4

49 um, iron, and zinc and diet diversity score (DDS) were used to assess diet quality.

50 The deceased donor score (DDS), expanded criteria donor (ECD) definition, and resi

51 fornia Department of Developmental Services (DDS) have been interpreted as supporting the hypothesis

52 orption (DVS) and dynamic dewpoint sorption (DDS) techniques.

53 n edema in dialysis disequilibrium syndrome (DDS) was investigated by diffusion-weighted magnetic res

54 Denys-Drash syndrome (DDS) is caused by dominant mutations of the Wilms' tumou

55 ncluding Wilms tumors, Denys-Drash syndrome (DDS), Frasier syndrome (FS) and WAGR syndrome (Wilms tum

56 , including dopamine dysregulation syndrome (DDS) and punding.

57 y-onset renal failure (Denys-Drash syndrome [DDS]).

58 )-based tumor-targeted drug delivery system (DDS) has been developed, which consists of a functionali

59 d photoresponsive dual drug delivery system (DDS) to release two different anticancer drugs (caffeic

60 organs, we proposed a drug delivery system (DDS) with specific targeting ligands for cancer cells.

61 acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise,

62 Advanced drug delivery systems (DDS) enhance treatment efficacy of different therapeutic

63 mitochondria-targeted drug delivery systems (DDS).

64 e-specific controlled drug delivery systems (DDSs) and has encouraged their rapid development in rece

65 in the development of drug delivery systems (DDSs) have been the short half-life, poor bioavailabilit

66 Among drug delivery systems (DDSs), smart nanocarriers that respond to specific stimu

67 ave been explored for drug delivery systems (DDSs).

68 The LHRH receptor targeting DDS did not show in vivo pituitary toxicity and did not

69 uously been proven that this tumor-targeting DDS works exactly as designed and shows high potency tow

70 Recently, it has been determined that DDS-resistant strains contain missense mutations in codo

71 The DDS data do not show any recent decrease in autism in Ca

72 The DDS data do not support the hypothesis that exposure to

73 The DDS-Tween-20 surface was simple and inexpensive to prepa

74 sion of basic oral science education for the DDS curriculum was established at the University at Buff

75 ism among children with active status in the DDS.

76 autism who were active status clients of the DDS from January 1, 1995, through March 31, 2007.

77 g the pharmacokinetic (PK) parameters of the DDS is essential to overcome these challenges.

78 The current review focuses on the DDS technologies, critical challenges, opportunities, st

79 fficient accumulation and penetration of the DDSs into the tumor tissue.

80 anding of the underlying mechanisms of these DDS approaches is expected to further contribute to this

81 To prove the efficacy of this DDS, three fluorescent and fluorogenic molecular probes

82 We examined three DDS associated mutations in ZF2 of human WT1 where the n

83 on of M. leprae and of its susceptibility to DDS from a single specimen.

84 on of M. leprae and of its susceptibility to DDS.

85 ivated therapies, especially light-triggered DDSs, relying on photoisomerization, photo-cross-linking

86 I stress the importance of understanding DDS on prey groups given the recent emergence of these s

87 Interestingly a mutation associated with DDS enhanced both -KTS WT1 binding to U2AF65 and splicin

88 The increased Dapp associated with DDS indicates that brain extracellular water increases a

89 skin and demonstrated a 93% correlation with DDS susceptibility as determined by both DNA sequencing

90 , were greatest in the group of kidneys with DDS > or = 20 pts.

91 nitive evidence linking these mutations with DDS resistance in M. leprae has been obtained.

92 ified a subgroup of ECD- kidneys, those with DDS > or = 20 pts, that functioned significantly below e